Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The “living drug” consists of tumor-infiltrating lymphocytes that can recognize and attack a patient’s specific cancer.
Studies are needed to evaluate the benefits and harms of promising new technologies and how to incorporate them into standard care.
A conversation with Dr. Alexandra-Chloé Villani about side effects melanoma patients may experience when receiving immunotherapy.
Margaret Taylor thanks University of Colorado Cancer Center’s Jennifer Diamond, MD, for putting her on a breast cancer clinical trial.
Scientists in many countries are working on vaccines to treat cancer, and more traditional vaccines protect against cancer-causing viruses.
The study seeks folks in the U.S. who have Lynch syndrome or a BRCA1 or BRCA2 mutation, linked to colorectal, breast & ovarian cancers.
21 public health groups ask Health and Human Services Office of Inspector General for regulatory reform to address the issue.
Resmetirom is the first drug to show both MASH resolution and fibrosis improvement in a late-stage clinical trial.
Participating in clinical trials for his metastatic prostate cancer, Drew Bouton has helped define the standard of care.
ACCE to “close the care gap” via clinical trials, cancer screenings and patient navigation services. Plus: A congressional resolution.
Patients who used adjuvant Keytruda had a reduced risk of recurrence and a 38% lower risk of death.
Coach Johnny Holland participates in a groundbreaking clinical trial at UCSF Health to treat his multiple myeloma, a type of blood cancer.
Strategies for oncology research community reflect urgent need to preserve, strengthen pandemic-era flexibilities.
“We can’t just be living longer if we’re not also living better,” says Stacy Fischer, MD, a CU Cancer Center leader.
Lack of awareness of and participation in clinical trials are the biggest obstacles to bringing new skin cancer therapies to market.
A look back at the most widely read science and treatment news we covered this year.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.